Effect of Danlou Tablets with good compliance to medical advice on the risk of short-term adverse cardiovascular events after PCI in patients with coronary heart disease

Early Phase 1

• Conditions: Coronary heart disease

• Registration Number: ITMCTR2024000221
• Lead Sponsor: Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1: Patients who were hospitalized for coronary heart disease and received PCI during hospitalization, or were hospitalized for other diseases but received PCI during hospitalization due to the appearance or aggravation of coronary heart disease symptoms, or were outpatients who received PCI for coronary heart disease in other hospitals within the past 2 weeks. Patients who met one of the above criteria and were diagnosed with phlegm and blood stasis syndrome by TCM met the inclusion criteria.

Exclusion Criteria

1) Aged over 80 years old 2) Combined with malignant tumors and other diseases that seriously affect survival expectations 3) Children, minors and pregnant women

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Short-term adverse cardiovascular events;